Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NXP900 + daraxonrasib
- Development stage
- Unknown
- Lead developer
- Nuvectis Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NXP900 + daraxonrasib is an investigational combination therapy being evaluated for the treatment of pancreatic cancer, specifically RAS-driven pancreatic ductal adenocarcinoma (PDAC). NXP900, developed by Nuvectis Pharma, is an oral, highly selective small-molecule inhibitor of SRC-family kinases (specifically SRC and YES1) that locks the target kinase in its native closed conformation (Type 1.5 inhibitor), blocking both its catalytic and scaffolding functions. Daraxonrasib (RMC-6236, brand name Rasonque), developed by Revolution Medicines, is an oral, multi-selective RAS(ON) inhibitor that acts as a non-degrading molecular glue, binding active RAS-GTP and suppressing downstream RAF-MEK-ERK and PI3K-AKT signaling. The combination is designed to target both the primary RAS driver and the SRC/YES1-mediated bypass resistance pathways. An investigator-sponsored trial (IST) of the combination is planned at two U.S. medical centers.
- Other names
- daraxonrasib + NXP900eCF506 + daraxonrasibeCF506 + RMC-6236NXP900 + RMC-6236NXP900 + RasonqueRMC-6236 + NXP900
02
Targets
HRAS (H-Ras protein)KRAS (Kirsten rat sarcoma viral oncogene homolog)NRAS (Neuroblastoma RAS viral oncogene homolog)PPIA (Peptidyl-prolyl cis-trans isomerase A)SRC (Proto-oncogene tyrosine-protein kinase Src)YES1 (YES proto-oncogene 1 tyrosine kinase)
Beyond the preview
Go deeper on NXP900 + daraxonrasib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NXP900 + daraxonrasib.